Search Results
Aug 25, 2025, 08:00 ET ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Givinostat Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a rare, progressive neuromuscular disorder caused by mutations in the DMD gene. Mutations in the DMD gene prevent the production of functional dystrophin, causing the dystrophin-associated protein complex (DAPC) to break down. This makes
More news about: ITF Therapeutics LLC
Aug 25, 2025, 08:00 ET Orsini Selected as Exclusive Specialty Pharmacy Partner for Ionis' DAWNZERA™ (donidalorsen)
first." About Orsini Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Aug 25, 2025, 06:32 ET Wingor Bio Lands Tens of Millions in Initial Funding with Round Still Open; Forges Ahead on Stem Cell Drug and Clinical Programs
/PRNewswire/ -- Shenzhen Wingor Biotechnology Co., Ltd. (hereinafter "Wingor Biotechnology"), a leading Chinese company in stem-cell and gene therapy, is pleased to announce significant progress in a financing round, raising dozens of millions in CNY. This round of financing is led
More news about: Wingor
Aug 25, 2025, 06:00 ET Bioinformatics-guided stool mRNA markers for CRC reported in Nature Portfolio journal Scientific Reports
using RT-qPCR on 114 clinical stool samples (33 CRC, 28 AA, 53 controls). The combined performance of the multi-gene mRNA panel was robust, achieving an Area Under the Curve (AUC) of 0.94 for discriminating CRC patients from controls, with 75.5% sensitivity and 95%
More news about: El Capitan Biosciences
Aug 25, 2025, 03:31 ET Leqembi® (lecanemab) launched in the EU today
involved in the metabolism of lipid in humans. It is implicated in AD. People with only one (heterozygous) or no copy (non-carriers) of the ApoE ε4 gene are less likely to experience ARIA than people with two ApoE ε4 copies (homozygous).ii ARIA is a recognized important side effect with lecanemab
More news about: BioArctic
Aug 25, 2025, 03:26 ET Leqembi® (lecanemab) launched in the EU today
involved in the metabolism of lipid in humans. It is implicated in AD. People with only one (heterozygous) or no copy (non-carriers) of the ApoE ε4 gene are less likely to experience ARIA than people with two ApoE ε4 copies (homozygous).ii ARIA is a recognized important side effect with lecanemab
More news about: BioArctic
Aug 24, 2025, 20:00 ET Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
cases. Although immunotherapy has significantly improved survival outcomes for some patients, those who do not respond to such treatments and lack driver gene mutations have limited therapeutic options, underscoring the urgent need for enhanced clinical interventions. Clinical research of the PD-1/IL-2α-biased
More news about: Innovent Biologics
Aug 23, 2025, 10:01 ET Biobanking Market worth $11.82 billion by 2030 with 9.1% CAGR | MarketsandMarkets™
contribute to the growth of the biobanking market, including growing focus on precision or personalized medicine, continuously expanding cell & gene therapy pipeline, and end-to-end automation for sample handling & storage. Additionally, the focus on sustainability and green-lab solutions offers
More news about: MarketsandMarkets
Aug 22, 2025, 14:49 ET SRPT Deadline: SRPT Investors with Losses in Excess of $100K Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial
More news about: THE ROSEN LAW FIRM, P. A.
Aug 22, 2025, 14:00 ET INVESTOR DEADLINE MONDAY: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT
Class Period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy ("Duchenne"), including ELEVIDYS (a prescription gene therapy intended for a limited category of people with Duchenne). The Sarepta Therapeutics class action lawsuit alleges that
More news about: Robbins Geller Rudman & Dowd LLP
Aug 22, 2025, 10:01 ET Epigenetics Market is expected to generate a revenue of USD 3.70 Billion by 2031, Globally, at 13.94% CAGR: Verified Market Research®
Global CGT Drugs Market Size By Therapy Type (Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy), By Application (Oncology, Genetic Disorders, Rare Diseases, Ophthalmology), By End-user (Hospitals, Cancer Care Centers,
More news about: Verified Market Research
Aug 22, 2025, 09:18 ET Cryptocurrencies to become an Essential Component of AMTD's War Chest of liquid funds totalling ~USD240 million; and TGE to focus into Crypto areas of Opportunities and Developments
on cryptocurrency-related opportunities and developments. A gene that has been built into its corporate name since inception, TGE represents
More news about: AMTD Digital; AMTD IDEA Group; The Generation Essentials Group
Aug 22, 2025, 08:45 ET Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Aug 21, 2025, 18:08 ET NORD's 2025 Rare Diseases & Orphan Products Breakthrough Summit to Spotlight CEOs, Investors, and Regulatory Leaders Driving Innovation
Innovation Center, U.S. Health and Human Services (HHS)Sean P. Nolan, Chief Executive Officer, Taysha Gene TherapiesMaha Radhakrishnan, M.D., Executive Partner, Sofinnova Investments Philip Ross,
More news about: National Organization for Rare Disorders (NORD®)
Aug 21, 2025, 17:32 ET Pivot Bio, Soil and Water Outcomes Fund Partner to Expand Acres
collaboration will enable farmers in Indiana and Illinois to use Pivot Bio's proprietary gene-edited nitrogen-fixing technology, PROVEN® 40 and PROVEN® G3 corn products, while participating in one of sustainable agriculture's
More news about: Pivot Bio, Inc
Aug 21, 2025, 16:30 ET INVESTOR DEADLINE AUGUST 25: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT
Class Period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy ("Duchenne"), including ELEVIDYS (a prescription gene therapy intended for a limited category of people with Duchenne). The Sarepta Therapeutics class action lawsuit alleges that
More news about: Robbins Geller Rudman & Dowd LLP
Aug 21, 2025, 10:37 ET RareCyte® Announces Research Grant to Investigate Molecular Profile of Circulating Trophoblasts in Fetal Growth Restriction
without interrupting pregnancy, and we do so while developing the capacity of young local talent and our research platform." The project aims to identify gene expression differences and molecular pathways involved in placental dysfunction, paving the way for improved diagnostics and potential therapeutic targets.
More news about: RareCyte, Inc.
Aug 21, 2025, 10:28 ET Mais colágeno e elastina: quais produtos e procedimentos ajudam a preservar essas proteínas tão preciosas para a pele?
Calame et al. Histological changes with extracellular matrix-remodeling topical therapy. Dermatol Case Rep 2017.12. Widgerow et al. Gene expression studies on extracellular matrix integrity: in vitro nuances. J Drugs Dermatol 2019.13. Widgerow AD, Jiang LI,
More news about: Galderma
Aug 21, 2025, 10:01 ET Tangential Flow Filtration Market worth $3.20 billion by 2030 with 11.4% CAGR | MarketsandMarkets™
the rising demand for scalable & high-throughput purification systems in biologics manufacturing. The growing pipeline of monoclonal antibodies, gene therapies, and recombinant proteins also drives the need for efficient concentration and buffer exchange methods. Additionally, increasing investments
More news about: MarketsandMarkets
Aug 21, 2025, 08:45 ET Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join - Contact The Gross Law Firm
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Aug 21, 2025, 08:30 ET AI in Molecular Biology: Revolutionizing the Future of Biotech, Upcoming Webinar Hosted by Xtalks
in biotechnology and life sciences. Attendees will learn how accelerated innovation facilitates breakthroughs in synthetic biology, drug discovery, gene therapy and other cutting-edge fields. The featured speaker will share how data-driven decisions empower scientists with predictive analytics and insights
More news about: Xtalks
Aug 21, 2025, 08:00 ET Andelyn Biosciences and Amplo Biotechnology Partner to Manufacture Novel Gene Therapies for Diseases Affecting the Neuromuscular Junction
treatments. About Andelyn Biosciences, Inc. Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization, and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn's deep scientific expertise has resulted in
More news about: Andelyn Biosciences
Aug 21, 2025, 07:23 ET Hamlet BioPharma Announces the Completion of the Alpha1H Phase II Study in Non-Muscle Invasive Bladder Cancer
Quantification of cell shedding in urine and the secondary endpoints included Induction of apoptosis, Histopathology scoring, Tumor response to Alpha1H by gene expression analysis, Proteomic analysis of immune markers in urine. Safety was assessed for all patients, who received treatment with investigational
More news about: Hamlet BioPharma AB (publ)
Aug 21, 2025, 07:00 ET Insmed To Present at September Investor Conferences
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater,
More news about: Insmed Incorporated
Aug 21, 2025, 02:49 ET Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Solutions